Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Interferon‐α combined with targeted therapies vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.3 [1.17, 1.45]
1 study · 416 participants
Low

Interferon‐α combined with targeted therapies vs standard targeted therapies

1‐year mortality · previously untreated patients with mRCC

Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.13 [0.95, 1.34]
1 study · 419 participants
Moderate

Interferon‐α combined with targeted therapies vs standard targeted therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found